Literature DB >> 21102269

Rapid and dramatic radiographic and clinical response to an ALK inhibitor (crizotinib, PF02341066) in an ALK translocation-positive patient with non-small cell lung cancer.

Sai-Hong Ignatius Ou1, Lyudmila Bazhenova, D Ross Camidge, Benjamin J Solomon, June Herman, Tatiana Kain, Yung-Jue Bang, Eunice L Kwak, Alice T Shaw, Ravi Salgia, Robert G Maki, Jeffrey W Clark, Keith D Wilner, A John Iafrate.   

Abstract

Entities:  

Mesh：

Substances：

Year:  2010        PMID： 21102269     DOI： 10.1097/JTO.0b013e318200f9ff

Source DB:  PubMed          Journal:  J Thorac Oncol        ISSN： 1556-0864            Impact factor:   15.609


× No keyword cloud information.
  31 in total

Review 1.  Phosphatidylinositol 3-kinase-AKT-mammalian target of rapamycin (PI3K-Akt-mTOR) signaling pathway in non-small cell lung cancer.

Authors:  Po Yee Yip
Journal:  Transl Lung Cancer Res       Date:  2015-04

Review 2.  Identification of cancer gene fusions based on advanced analysis of the human genome or transcriptome.

Authors:  Lu Wang
Journal:  Front Med       Date:  2013-06-26       Impact factor: 4.592

3.  Genetic testing for lung cancer: reflex versus clinical selection.

Authors:  Paul A Bunn; Robert C Doebele
Journal:  J Clin Oncol       Date:  2011-04-11       Impact factor: 44.544

Review 4.  Fluid biopsy for solid tumors: a patient's companion for lifelong characterization of their disease.

Authors:  Jorge J Nieva; Peter Kuhn
Journal:  Future Oncol       Date:  2012-08       Impact factor: 3.404

5.  Ultrasmall Core-Shell Silica Nanoparticles for Precision Drug Delivery in a High-Grade Malignant Brain Tumor Model.

Authors:  Rupa Juthani; Brian Madajewski; Barney Yoo; Ulrich Wiesner; Michelle S Bradbury; Cameron W Brennan; Li Zhang; Pei-Ming Chen; Feng Chen; Melik Z Turker; Kai Ma; Michael Overholtzer; Valerie A Longo; Sean Carlin; Virginia Aragon-Sanabria; Jason Huse; Mithat Gonen; Pat Zanzonico; Charles M Rudin
Journal:  Clin Cancer Res       Date:  2019-09-12       Impact factor: 12.531

Review 6.  Brain metastases in non-small-cell lung cancer: are tyrosine kinase inhibitors and checkpoint inhibitors now viable options?

Authors:  S Morin-Ben Abdallah; A Wong
Journal:  Curr Oncol       Date:  2018-06-13       Impact factor: 3.677

7.  Induction of autophagy contributes to crizotinib resistance in ALK-positive lung cancer.

Authors:  Cheng Ji; Li Zhang; Yan Cheng; Raj Patel; Hao Wu; Yi Zhang; Mian Wang; Shundong Ji; Chandra P Belani; Jin-Ming Yang; Xingcong Ren
Journal:  Cancer Biol Ther       Date:  2014-02-20       Impact factor: 4.742

8.  Crizotinib (PF02341066) as a ALK /MET inhibitor- Special Emphasis as a Therapeutic Drug Against Lung Cancer.

Authors:  Tobenna Nwizu; Rajani Kanteti; Ichiro Kawada; Cleo Rolle; Everett E Vokes; Ravi Salgia
Journal:  Drugs Future       Date:  2011-02       Impact factor: 0.148

Review 9.  Mechanistic insight into ALK receptor tyrosine kinase in human cancer biology.

Authors:  Bengt Hallberg; Ruth H Palmer
Journal:  Nat Rev Cancer       Date:  2013-10       Impact factor: 60.716

Review 10.  Anaplastic lymphoma kinase: Role in cancer and therapy perspective.

Authors:  Zhihong Zhao; Vivek Verma; Mutian Zhang
Journal:  Cancer Biol Ther       Date:  2015       Impact factor: 4.742
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.